文献速递颈动脉与弓上血管

颈动脉内膜切除术前他汀与抗血小板药物使用不影响术后结局

Preoperative Antiplatelet and Statin Use Does Not Affect Outcomes after Carotid Endarterectomy.
PubMed 文献 · Ann Vasc Surg · 2017-11-01

基于美国外科医师学会国家手术质量改进计划靶向颈动脉内膜切除(CEA)数据库2011至2014年13521例CEA患者,评估术前他汀与抗血小板药物使用率及其对围手术期结局的影响。多因素分析显示,术前他汀或抗血小板使用均未独立影响30天死亡率、围手术期心肌梗死、卒中或主要不良心血管事件(MACE)。

要点

  • 术前他汀使用率80.5%,抗血小板使用率89.3%,合并症多和无症状患者中使用更常见。
  • 多因素分析显示术前他汀使用未独立影响30天死亡、心梗、卒中或MACE。
  • 多因素分析显示术前抗血小板使用未独立影响30天死亡、心梗、卒中或MACE。

核心结论

  • 术前他汀和抗血小板使用在合并症较多和无症状的CEA患者中更常见,可能反映更密切的随访和 primary care 参与。
  • 术前他汀和抗血小板使用未影响围手术期结局,提示其短期使用并非必需。
  • 未使用他汀或抗血小板的患者可在考虑启动这些药物之前安全地接受CEA。

研究设计与样本

  • 回顾性队列研究,查询美国外科医师学会国家手术质量改进计划(ACS NSQIP)靶向CEA数据库2011至2014年数据。
  • 共纳入13521例CEA患者,平均年龄71岁,男性占61.5%,无症状患者占57.9%。
  • 采用多因素分析评估术前他汀和抗血小板使用对CEA结局的影响。

主要发现

  • 术前他汀使用率80.5%,抗血小板使用率89.3%。
  • 他汀使用在较高BMI、独立功能状态、糖尿病、高血压、出血性疾病或抗凝、非吸烟者和无症状患者中更常见(P < 0.05)。
  • 抗血小板使用在男性、非吸烟、糖尿病、高血压、慢性阻塞性肺疾病、呼吸困难和无症状颈动脉疾病中更常见。
  • 单因素分析中,他汀使用与术后心肌梗死(1.9% vs. 1.4%,P = 0.085)、卒中(1.8% vs. 1.9%,P = 0.55)、短暂性脑缺血发作(TIA)(0.9% vs. 1.1%)或MACE(4% vs. 3.6%)无关。
  • 单因素分析中,抗血小板使用对30天死亡率(0.7% vs. 1%,P = 0.28)、心肌梗死(1.9% vs. 1.7%,P = 0.73)、卒中(1.8% vs. 1.8%,P = 0.94)、TIA(0.9% vs. 1%,P = 0.63)或MACE(3.9% vs. 4%,P = 0.8)无影响。

关键数值与推荐

  • 多因素分析:术前他汀使用未独立影响30天死亡率(OR 0.94,95%CI 0.55-1.6,P = 0.825)。
  • 多因素分析:术前他汀使用未独立影响围手术期心肌梗死(OR 1.1,95%CI 0.77-1.58,P = 0.573)。
  • 多因素分析:术前他汀使用未独立影响卒中(OR 0.891,95%CI 0.64-1.2,P = 0.42)。
  • 多因素分析:术前他汀使用未独立影响MACE(OR 1.03,95%CI 0.81-1.32,P = 0.806)。
  • 多因素分析:术前抗血小板使用未独立影响30天死亡率(OR 0.67,95%CI 0.37-1.3,P = 0.19)、围手术期心肌梗死(OR 0.9,95%CI 0.59-1.38,P = 0.637)、卒中(OR 0.92,95%CI 0.61-1.4,P = 0.69)或MACE(OR 0.88,95%CI 0.66-1.18,P = 0.39)。

临床怎么用

  • 对于未使用他汀或抗血小板药物的CEA患者,可在考虑启动这些药物之前安全进行手术。
  • 术前他汀或抗血小板药物的短期使用并非CEA围手术期结局的必要条件。
  • 合并症较多和无症状患者术前他汀和抗血小板使用率更高,可能反映更密切的初级保健随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of statin and antiplatelet medications has been advocated in patients with cerebrovascular disease as primary medical therapy and as an adjunct to carotid endarterectomy (CEA). Our goal was to assess the prevalence of preoperative statin and antiplatelet use and its effect on perioperative outcomes after CEA. METHODS: The American College of Surgeons National Surgical Quality Improvement Program targeted CEA database was queried for patients undergoing CEA between 2011 and 2014. Multivariable analysis was used to assess the effect of preoperative statin and antiplatelet use on CEA. RESULTS: There were 13,521 CEAs identified. The average age was 71 years, and 61.5% were male. More than half of patients (57.9%) were asymptomatic. Preoperative statin use was seen in 80.5% of patients, and antiplatelet use was seen in 89.3% of patients. Statin use was more common in patients with higher body mass index, independent functional status, diabetes, hypertension, bleeding disorders or anticoagulation, nonsmokers, and asymptomatic patients (P < 0.05). On univariate analysis, statin use was not associated with postoperative myocardial infarction (MI) (1.9% vs. 1.4%, P = 0.085), stroke (1.8% vs. 1.9%, P = 0.55), transient ischemic attack (TIA) (0.9% vs. 1.1%), or major adverse cardiovascular events (MACE) (4% vs. 3.6%). On multivariate analysis, preoperative statin use did not independently affect 30-day mortality (odds ratio [OR]: 0.94, 95% confidence interval [CI]: 0.55-1.6, P = 0.825), perioperative MI (OR 1.1, 95% CI 0.77-1.58, P = 0.573), stroke (OR: 0.891, 95% CI: 0.64-1.2, P = 0.42), or MACE (OR 1.03, 95% CI: 0.81-1.32, P = 0.806). Antiplatelet use was more common with male gender, nonsmoking, diabetes, hypertension, chronic obstructive pulmonary disease, dyspnea, and asymptomatic carotid disease. On univariate analysis, antiplatelet use showed no effect on 30-day mortality (0.7% vs. 1%, P = 0.28), MI (1.9% vs. 1.7%, P = 0.73), stroke (1.8% vs. 1.8%, P = 0.94), TIA (0.9% vs. 1%, P = 0.63), or MACE (3.9% vs. 4%, P = 0.8). On multivariate analysis, preoperative antiplatelet use did not independently affect 30-day mortality (OR: 0.67, 95% CI: 0.37-1.3, P = 0.19), perioperative MI (OR: 0.9, 95% CI: 0.59-1.38, P = 0.637), stroke (OR: 0.92, 95% CI: 0.61-1.4, P = 0.69), or MACE (OR: 0.88, 95% CI: 0.66-1.18, P = 0.39). CONCLUSIONS: Preoperative statin and antiplatelet use in patients undergoing CEA was more often observed in patients with higher rates of comorbidities and asymptomatic disease, and this may represent closer follow-up and engagement with primary care physicians in this patient cohort. Preoperative statin and antiplatelet use did not affect perioperative outcomes suggesting that its short-term use is not essential. In patients who are not on statins or antiplatelet medications, CEA can safely be performed before consideration is given to their initiation.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Krafcik BM, Farber A, Eberhardt RT, et al. Preoperative Antiplatelet and Statin Use Does Not Affect Outcomes after Carotid Endarterectomy. Ann Vasc Surg. 2017. PMID: 29100876. doi:10.1016/j.avsg.2017.10.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。